A Study to Evaluate ALN-6222 in Participants With Obesity | Clinical Trial | StuddyBuddy@endsection A Study to Evaluate ALN-6222 in Participants With Obesity
Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT07624071

A Study to Evaluate ALN-6222 in Participants With Obesity

Conditions: Obesity

Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: No
Phase: PHASE1
Enrollment: 88
Sponsor: Alnylam Pharmaceuticals

Location: Clinical Trial Site Mount Royal

Summary

This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.

Eligibility Criteria

Inclusion Criteria - * Is an adult patient with a body mass index ≥30 kg/m\^2 to \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07624071). StuddyBuddy aggregates publicly available trial information.